Penn PET Addiction Center of Excellence (Penn PACE)

宾夕法尼亚州 PET 成瘾卓越中心 (Penn PACE)

• 批准号: 10449220
• 负责人: HENRY RICHARD KRANZLER
• 金额: $ 184.32万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10449220
• 关键词: Area; Biological Markers; Biometry; Brain; Buprenorphine; Caring; Clinical; Clinical Data; Clinical Management; Clinical Research; Collaborations; Complex; Controlled Clinical Trials; Coupled; Data; Data Analyses; Depression and Suicide; Development; Disease; Dose; Ensure; Epidemic; Evaluation; Experimental Designs; Faculty; Feeling suicidal; Foundations; Funding; Future; Genetic Variation; Goals; Grant; HIV; HIV Infections; Harm Reduction; Heart; Image; Individual Differences; Infrastructure; Lead; Mental Depression; Mentorship; Methadone; Modeling; Monitor; Morbidity - disease rate; Names; National Institute of Drug Abuse; Neurobiology; Operations Research; Opiate Addiction; Opioid; Opioid Receptor; Overdose; Oxidative Stress; Participant; Patient Care; Patients; Pennsylvania; Persons; Pharmaceutical Preparations; Pilot Projects; Positron-Emission Tomography; Process; Productivity; Psychiatry; Radiochemistry; Radiology Specialty; Recording of previous events; Request for Applications; Research; Research Personnel; Resources; Risk; Role; Scanning; Science; Scientist; Services; Strategic Planning; Suicide; Technical Expertise; Therapeutic; Toxic effect; Training; Training Programs; Translational Research; Translations; Treatment outcome; United States National Institutes of Health; Universities; addiction; base; career; career development; clinical care; clinical infrastructure; comorbidity; delta opioid receptor; design; disorder later incidence prevention; dosimetry; illicit opioid; image processing; imaging properties; imaging scientist; imaging study; improved; individualized medicine; innovation; instrumentation; interdisciplinary collaboration; kappa opioid receptors; medical schools; molecular imaging; mortality; neurobiological mechanism; neurochemistry; neuroimaging; neuroinflammation; next generation; novel strategies; opioid use disorder; pain relief; prescription opioid; professor; programs; radiotracer; ranpirnase; receptor; recruit; response; suicidal risk; synergism; treatment response; treatment trial

OVERALL ABSTRACT This is a revised application requesting resources to create a NIDA P30 Core Center of Excellence Program at the University of Pennsylvania focused on studying the neurobiology of opiate use disorders (OUDs). This new center will focus on Positron Emission Tomography (PET) studies in patients seeking treatment at the Center for the Studies of Addiction (CSA) at the Perelman School of Medicine. The University of Pennsylvania has a long history in two key areas that serve as the foundation of this P30 Center of Excellence, the development of novel strategies for the opiate use disorders, and PET imaging studies of brain function. The name of the proposed center is the Penn PET Addiction Center of Excellence (Penn PACE), and represents a collaborative effort between the Departments of Radiology and Psychiatry at Penn. A key addition to this revised application is the inclusion of Yale University in this P30 Center. The center will initially focus on opioid receptors in opioid sensitivity, addiction, and suicide, and the role of oxidative stress and neuroinflammation in OUDs. This center takes advantage of unique resources at both the University of Pennsylvania and Yale University. The PIs of the Center are Dr. Robert H. Mach, the Britton Chance Professor of Radiology, Dr. Henry Kranzler, the Benjamin Rush Professor of Psychiatry, and Dr. Caryn Lerman, the John Glick Professor of Psychiatry and Vice Dean for Strategic Initiatives at Penn. Another key person is Dr. Richard Carson of the Yale University PET Center; Dr. Carson will lead the research effort at Yale University and direct the data analysis component of the Imaging Core. He is also the Co-Director of the Imaging Core with Dr. David Mankoff at Penn. The center consists of an Administrative Core and three research cores: Radiochemistry, Imaging and Clinical Core. Central to this center is the Pilot Project Core, which consists of a panel of identified and potential pilot projects by NIDA-funded investigators who use the opportunities provided by this P30 Core Center of Excellence Program to expand their research programs. We anticipate that the Penn PACE will lead to a significant advance in our understanding of the neurobiological mechanisms of opiate use disorders and neuroinflammation in a manner only possible through the combination of tightly-controlled clinical trials coupled with the unique molecular imaging properties provided by PET.

总体摘要 这是一份修订后的申请，要求提供资源，以创建NIDA P30核心卓越中心 宾夕法尼亚大学的一个项目专注于研究鸦片使用障碍的神经生物学 （OUD）。这个新的中心将专注于正电子发射断层扫描（PET）研究的患者寻求 在佩雷尔曼医学院成瘾研究中心（CSA）接受治疗。的 宾夕法尼亚大学在两个关键领域有着悠久的历史，这两个领域是P30的基础 卓越中心，开发阿片类药物使用障碍的新策略，以及PET成像 大脑功能的研究。拟议中的中心的名称是宾州PET成瘾中心， 卓越（Penn PACE），并代表放射科之间的合作努力 和宾夕法尼亚大学的精神病学一个关键的补充，这一修订后的应用程序是包括耶鲁大学， P30中心该中心最初将专注于阿片受体在阿片类药物敏感性，成瘾， 自杀，以及氧化应激和神经炎症在OUD中的作用。这个中心利用 宾夕法尼亚大学和耶鲁大学的独特资源。中心的PI 罗伯特·H博士马赫，布里顿机会放射学教授，亨利克兰兹勒博士，本杰明 拉什精神病学教授，和博士卡琳勒曼，精神病学和副约翰格里克教授 宾夕法尼亚大学战略计划系主任另一个关键人物是耶鲁大学的理查德卡森博士 PET中心;卡森博士将领导耶鲁大学的研究工作，并指导数据分析 成像核心的组成部分。他也是大卫曼科夫博士的成像核心的联合主任 在宾夕法尼亚大学。该中心由一个行政核心和三个研究核心组成：放射化学， 影像学和临床核心。该中心的核心是试点项目核心，其中包括一个小组， 由NIDA资助的研究人员利用提供的机会确定和潜在的试点项目 通过这个卓越计划的P30核心中心，以扩大他们的研究计划。我们预计 宾夕法尼亚大学的PACE将使我们对神经生物学机制的理解取得重大进展 阿片类药物使用障碍和神经炎症的方式，只有通过结合 严格控制的临床试验加上PET提供的独特分子成像特性。